About
Genetically targeted medicine
Areas of Focus
Categories
Small Molecule PharmaceuticalSoutheastern U.S.
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
8,490
By Phase
PHASE3: 2PHASE2: 1NA: 1
By Status
COMPLETED: 2RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05918861Lead Sponsor
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
PHASE3Recruiting
2,000 participants
Started: Oct 3, 2023 · Completed: Aug 31, 2027
NCT04676867Lead Sponsor
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
PHASE2Completed
227 participants
Started: Jan 11, 2021 · Completed: May 17, 2021
NCT04596124Lead Sponsor
Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze
NAUnknown
116 participants
Started: Sep 18, 2020 · Completed: Sep 18, 2022
NCT02525939Lead Sponsor
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
PHASE3Completed
6,147 participants
Started: Apr 30, 2016 · Completed: Oct 31, 2021
Locations (1)
Headquarters
Sarasota, FL, United States
Map
Loading map...